News | December 27, 2025
The state-of-the-art facility is expected to be commissioned over the next three years
The company operates a chain of mid-sized multi-speciality hospitals
The plant can reach an annual capacity of 300 crore tablets and 90 crore capsules
LNK01006 is designed to deliver potent, selective inhibition of TYK2-mediated cytokine signaling with central nervous system exposure
Biocon will acquire all of Viatris’ convertible preferred equity in Biocon Biologics for $400 million in cash and $415 million in newly issued Biocon shares
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
Selected proposals in the innovation challenge will receive funding to develop transformative ideas, tools, and approaches to strengthen early diagnosis and improve patient outcomes
Subscribe To Our Newsletter & Stay Updated
